← Back to patent-cliff list
Orziloben
Tier C — Watch / tradeOrziloben
Pronova Biopharma Norge As
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Liver disease, 短肠综合征
Regional status
US
Phase II
2024-01-15
EU
Phase I
2021-12-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Orziloben?
Approved indications include: Liver disease, 短肠综合征.
When does the Orziloben patent expire?
No public expiry year is available for Orziloben yet; this page updates once verified.
How do I get a quote for Orziloben intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02